Lung Cancer Therapy Annual 7

<p><strong>Highly Commended BMA Medical Book Awards 2013</strong></p><p>Oncology research and practice in lung cancer continues to develop rapidly. This latest edition of an acclaimed reference briefs the oncology community with a review of the recent literature emphasizing the most significant therapeutic advances. The expert contributions of<b> </b><strong>Lung Cancer Therapy Annual</strong> <b>7 </b>offer an update of the impact that this information will have on the day-to-day management of the lung cancer patient. </p><p>New to the seventh edition are four new chapters on the treatment of non-small cell lung cancer (NSCLC) and a new chapter on thymoma. Additional topics include:</p><ul> <p> </p> <li>Oncogenic driver mutations </li> <p> </p> <li>First line therapy of advanced non-small cell lung cancer without activating EGFR mutation</li> <p> </p> <li>Second line therapy of non-small cell lung cancer</li> <p> </p> <li>Adjunct and neoadjunct therapy of non-small cell lung cancer</li> <p> </p> <li>Advances in surgery of lung cancer; advances in radiotherapy of lung cancer </li> <p> </p> <li>Mesothelioma</li> <p> </p> <li>Thymic tumors</li> </ul>